DeFeudis, F. V. Clinical Studies and Clinical Pharmacology with Egb 761, ibid. pp. 97-125. |
DeFeudis, F. V. In Vitro Studies with EGb 761, in Ginkgo biloba Extract (Egb761): Pharmacological Activities and Clinical Applications, F. V. DeFeudis, Elsevier, Paris 1991, pp. 25-60. |
DeFeudis, F. V. In Vivo Studies with EGb 761, in Ginkgo biloba Extract (EGb 761): Pharmacological Activities and Clinical Applications, F. V. DeFeudis, Elsevier, Paris 1991, pp. 61-78. |
DeFeudis, F. V. Machanisms and Concepts of Action of Egb 761: Theoretical Considerations, ibid. pp. 147-152. |
DeFeudis, F. V. Safty of Egb 761-Containing Products, ibid, pp. 143-146. |
Pietri,S.et al, Effect of Ginkgo biloba extract (Egb 761) on tree radical-induced ischemia-repertusion injury in isolated rat hearts: a hemodynamic and electron-spin-resonance investigation, in advances in Ginkgo biloba Extract Research, vol. 2, Ginkgo biloba Extract (Egb 761) as a Free-Radical Scavenger, C. Ferradini et al. eds, Elsevier, Paris 1993, pp. 163-171. |
Spinnewyn, B. et al, Effect of Ginkgo biloba extract (Egb 761) on oxygen consumption by isolated cerebral mitochondria, in Advances in Ginkgo biloba Extract Research, vol. 4. Effacts of Ginkgo biloba Extract (Egb 761) on Aging and age-Related Disorders, Y. Christen et al. eds, Elsevier, Paris, 1995, pp. 17-22. |
Xie, De Long et al. Ginkgo Biloba Composition, Method to Prepare the Same and Uses Thereof U.S. Ser. No.: 09/097,058; Filing Date Jun. 12, 1998 claiming for priority of U.S. Ser. No.: 09/044,551 filed on Mar. 19, 1998, now U.S. patent 6,030,621 issued on Feb. 29, 2000. |